REFERENCES
- Li Z, Turner RP, Smith G. Childhood paroxysmal kinesigenic dyskinesia: report of seven cases with onset at an early age. Epilepsy Behav. 2005;6:435–9.
- Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, Lynch DR, Mathews KD, Swoboda KJ, Harris J, Soong BW, Ashizawa T, Jankovic J, Renner D, Fu YH, Ptacek LJ. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology. 2004;63:2280–87.
- Margari L, Presicci A, Ventura P, Margari F, Perniola T. Channelopathy: hypothesis of a common pathophysiologic mechanism in different forms of paroxysmal dyskinesia. Pediatr Neurol. 2005;32:229–35.
- Mir P, Huang YZ, Gilio F, Edwards MJ, Berardelli A, Rothwell JC, Bhatia KP. Abnormal cortical and spinal inhibition in paroxysmal kinesigenic dyskinesia. Brain. 2005;128:291–9.
- Zorzi G, Conti C, Erba A, Granata T, Angelini L, Nardocci N. Paroxysmal dyskinesias in childhood. Pediatr Neurol. 2003;28:168–72.
- Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995;38:571–9.
- Houser MK, Soland VL, Bhatia KP, Quinn NP, Marsden CD. Paroxysmal kinesigenic choreoathetosis: a report of 26 patients. J Neurol. 1999;246:120–26.
- Bhatia KP. Paroxysmal dyskinesias. Movement Disorders. 2011;26:1157–65.
- Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. 2004;5:627–35.
- Shorvon S. Oxcarbazepine: a review. Seizure. 2000;9:75–9.
- Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3:70–76.
- Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. 1987;1:284–9.
- Gokcay A, Gokcay F. Oxcarbazepine therapy in paroxysmal kinesigenic choreoathetosis. Acta Neurol Scand. 2000;101: 344–5.
- Chillag KL, Deroos ST. Oxcarbazepine use in paroxysmal kinesigenic dyskinesia: report on four patients. Pediatr Neurol. 2009;40:295–7.
- Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009:CD006453.
- Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015.
- Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005;252:1299–306.
- Kalis MM, Huff NA. Oxcarbazepine: an antiepileptic agent. Clin Ther. 2001;23:680–700; discussion 645.